Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher
Crossref DOI link: https://doi.org/10.1007/s10557-016-6685-y
Published Online: 2016-09-13
Published Print: 2016-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Ginsberg, Henry N.
Rader, Daniel J.
Raal, Frederick J.
Guyton, John R.
Baccara-Dinet, Marie T.
Lorenzato, Christelle
Pordy, Robert
Stroes, Erik
Funding for this research was provided by:
Sanofi and Regeneron Pharmaceuticals Inc.
License valid from 2016-09-13